cBlastomyces spp. antigen testing was evaluated over a 10-year period in an area where blastomycosis is endemic. Antigen testing was less sensitive than previously reported, but serial urine testing was useful in monitoring disease resolution or progression. Culture and cytopathology remain the gold standard for diagnosis and exclusion of this infection.
Blastomycosis is a serious and potentially fatal fungal infection. Blastomycosis may be asymptomatic or it can present as isolated pulmonary disease, disseminated disease (pulmonary and extrapulmonary infection), or extrapulmonary disease with manifestations in the central nervous system, bone, skin, or other locations (1-11).Culture and cytopathology are the gold standard for the diagnosis of blastomycosis. However, a variety of other diagnostic tests, including antigen testing, antibody testing, and PCR, are commercially available (8,(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). Given that identification from culture may not be evident for 2 to 4 weeks and that it often requires invasive procedures to obtain specimens, there is great interest in using antigen enzyme immunoassays (EIA) for rapid, noninvasive diagnosis and monitoring of disease progression or resolution (2,4,8,19).We evaluated the use of Blastomyces urine, serum, and bronchoalveolar lavage (BAL) fluid antigen assays for the diagnosis of blastomycosis and the effects of treatment on the clearance of antigenuria at the Marshfield Clinic from 1995 to 2015. Marshfield Clinic is located in Wisconsin where blastomycosis is endemic (1,3,6,9,(23)(24)(25)(26)(27)(28). Research protocols were approved by the Marshfield Clinic Institutional Review Board. Waiver of informed consent was obtained.Patients were included if blastomycosis was confirmed by culture or cytopathology and if urine, serum, or BAL fluid antigen EIA was completed at the time of diagnosis or within 30 days of starting antifungal medication. Blastomycosis was confirmed by culture or cytopathology at Marshfield Labs using conventional techniques. Commercially available blastomycosis antigen EIA was performed at the MiraVista Diagnostics reference laboratory at the time of specimen collection using qualitative EIA prior to March 2011 or quantitative EIA thereafter. EIA results are available within 24 h of sample submission (13,14,16). All specimens were obtained as part of routine clinical evaluations. Retrospective chart review was completed for all patients.Data were abstracted into Excel 2010, and statistical analysis was completed using SAS 9.3. Categorical data were compared using the 2 test or the Fisher exact test. Continuous variables were compared using Wilcoxon rank sum, Kruskal-Wallis, or analysis of variance (ANOVA). Correlation for serial urine antigen testing was measured using Spearman's coefficient. Significance was defined as a P of Ͻ0.05.Patients with quantitative antigen EIA results were reported as negative, positive below the limit of quantification (Ͻ0.2 ng/ml), positive and quantifiable (0.2 to 14.7 ng/ml), or positiv...